Tesamorelin / Ipamorelin GH-axis research blend
Tesamorelin / Ipamorelin Blend
Research blend of Tesamorelin (5 mg) + Ipamorelin (5 mg) supplied as a lyophilized single-vial preparation, 10 mg total peptide mass
Overview
The Tesamorelin / Ipamorelin Blend combines two GH-axis peptides at 5 mg each in a single lyophilized vial. The pairing is mechanistically similar to the CJC-1295 / Ipamorelin blend — dual-pathway GH stimulation combining a GHRH-analogue with a ghrelin-receptor agonist — but with a Tesamorelin backbone chosen specifically for its documented visceral-fat-reduction pharmacology. Tesamorelin's peer-reviewed evidence base is anchored in the Falutz 2007 NEJM pivotal trial and the Stanley 2014 JAMA sustained-effect follow-up. That component-level evidence is the reason Tesamorelin, rather than CJC-1295, is the GHRH-analogue component of this specific blend.
The dose trade-off in the 1:1 vial ratio is worth naming honestly. Tesamorelin's research reference amount is 2 mg subcutaneously daily. Ipamorelin's optimal amount per injection is 0.25–0.375 mg. In this 5/5 mg blend, reaching the 2 mg Tesamorelin amount requires injecting 0.4 mL of the reconstituted blend, which delivers 1 mg of Ipamorelin — well above its optimal range. Conversely, holding Ipamorelin at its optimal 0.25–0.375 mg (0.1–0.15 mL of blend) delivers only 0.25–0.375 mg of Tesamorelin — well below its research reference. The practical compromise the Healthy Mango practitioner reference recommends is 0.2 mL per injection, delivering 0.5 mg of each — Tesamorelin below its research reference and Ipamorelin above its optimal.
For researchers new to GH-axis peptides during titration, this compromise dose is often reasonable — it introduces both peptides without overshooting either significantly, and it accepts that Tesamorelin's full documented effect may not be reached at the blend's compromise dose. For researchers targeting the full Tesamorelin visceral-fat-reduction effect, running the two peptides separately would give more control — Tesamorelin at its 2 mg research reference and Ipamorelin at its optimal 0.25–0.375 mg per injection.
Blend-specific human trial evidence does not exist. Component-level evidence is substantial for Tesamorelin (Falutz 2007 NEJM, Stanley 2014 JAMA) and characterised for Ipamorelin (Raun 1998). The combination has not been formally evaluated as a single product. That is the honest evidence framing; the mechanistic rationale for dual-pathway GH stimulation is coherent, and component-level evidence does not automatically transfer to the combination.
Quick Facts & Evidence
- Category
- Tesamorelin / Ipamorelin GH-axis research blend
- Research area
- Research blend
- Most studied for
- Visceral fat reduction (Tesamorelin's documented research signal)
- Body composition
- IGF-1 elevation
- Metabolic support in insulin-resistance / lipid-profile contexts
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Early Human Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Early Human Evidence
Small-scale human studies, observational data, or off-label case reports only. Substantial uncertainty remains.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format (two-component blend)
This page covers the RUO lyophilized Tesamorelin + Ipamorelin blend vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. The 1:1 mass ratio creates an unavoidable per-injection compromise between the two ingredients' individually optimal windows — the Guide is explicit about this trade-off.
Tesamorelin / Ipamorelin Blend research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 10 mg total (Tesamorelin 5 mg + Ipamorelin 5 mg) |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 2.0 mL |
| Final concentration (each ingredient) | 2.5 mg/mL of Tesamorelin and 2.5 mg/mL of Ipamorelin |
| How it's given | Subcutaneous injection |
| Practical dose | 20 units = 0.5 mg of each ingredient per injection (compromise) |
| Compromise note | Tesamorelin standalone optimum is ~2 mg; blend delivers only ~25% of that |
| Frequency | Daily or 5× per week |
| Cycling | Continuous daily dosing follows Tesamorelin's standard protocol |
Reported Dosing
The practitioner-reference research protocol is 0.5 mg of each ingredient per injection (20 units), daily or 5× per week, run continuously per Tesamorelin's standard protocol. This is a compromise dose — Tesamorelin's clinical standard is 2 mg, so blend use delivers roughly 25% of the standalone Tesamorelin optimum. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 0.5 mg each (Tesamorelin + Ipamorelin) | Daily, subcutaneous | Continuous — matches Tesamorelin's standard protocol | 0.2 mL at 2.5 mg/mL each; the compromise dose |
| 0.5 mg each (Tesamorelin + Ipamorelin) | 5× per week, subcutaneous | Continuous — matches Tesamorelin's standard protocol | Same volume; reduced frequency also documented |
Why protocols vary
The 1:1 mass ratio creates an unavoidable trade-off. Tesamorelin's clinical standard (Falutz 2007; Stanley 2014) is 2 mg once daily; Ipamorelin's optimal window is 0.25–0.375 mg per injection. At the 20-unit compromise, Tesamorelin is dosed at only ~25% of its standalone optimum and Ipamorelin sits slightly above its optimal window.
Users seeking the full Tesamorelin standalone optimum typically dose the individual Tesamorelin vial in parallel rather than doubling the blend volume; the Guide notes that new patients being titrated on Tesamorelin are better served by the standalone product.
Continuous daily dosing follows Tesamorelin's standard protocol; the blend does not introduce a separate cycling requirement.
Preparing the Solution
Turning the freeze-dried blend into a measurable liquid.
Blend composition
10 mg total peptide (Tesamorelin 5 mg + Ipamorelin 5 mg)
The vial holds two lyophilized peptides in the same cake. Reconstituting with 2.0 mL of bacteriostatic water dissolves both at once and gives 2.5 mg/mL of each ingredient; a single injection volume delivers both in parallel.
Tesamorelin
- Mass in vial
- 5 mg
- Share of total
- 50%
- Concentration after mixing
- 2.5 mg/mL
- Reported per-injection dose
- 0.5 mg per injection (compromise; ~25% of the 2 mg standalone optimum)
Ipamorelin
- Mass in vial
- 5 mg
- Share of total
- 50%
- Concentration after mixing
- 2.5 mg/mL
- Reported per-injection dose
- 0.5 mg per injection (slightly above the 0.25–0.375 mg optimal window)
One reconstitution, one injection volume — but the 1:1 mass ratio creates an unavoidable trade-off. At 20 units (0.5 mg each) Tesamorelin is underdosed relative to its 2 mg clinical standard; at 40 units (0.5 mL, giving Tesamorelin its optimum) Ipamorelin would be substantially overdosed. Practitioner-reference practice uses 20 units as the compromise.
Documented in the practitioner reference (chapter 29)
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 10 mg blend vial (5 mg Tesamorelin + 5 mg Ipamorelin)
Diluent: 2.0 mL bacteriostatic water
Final concentration: 5 mg/mL total (2.5 mg/mL each)
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
2mL
Resulting concentration
5 mg/mL
Equivalent volume
The reported research amount of 1 mg is contained within
0.2mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 10 mg ÷ 2 mL = 5 mg/mL
- Bacteriostatic water to match the documented concentration
- 10 mg ÷ 5 mg/mL = 2 mL
- Equivalent volume at this concentration
- 1 mg ÷ 5 mg/mL = 0.2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner reference (total-blend arithmetic; the 20-unit compromise dose delivers 1 mg total per injection = 0.5 mg of each ingredient)Research-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO blend preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, daily or 5× per week
Documented in the practitioner reference · Research-practitioner guide
Why this method
Tesamorelin is a 44-amino-acid GHRH analogue and Ipamorelin is a 5-amino-acid ghrelin-receptor agonist; both would be degraded by gastrointestinal proteolysis, so the subcutaneous route delivers them into circulation intact for pituitary signalling.
Continuous daily dosing matches Tesamorelin's approved-product cadence in HIV-associated lipodystrophy (Egrifta), which the Guide uses as the cadence anchor for the blend.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling. Approved Tesamorelin (Egrifta / Egrifta SV) has its own labelled storage window and does not apply to this RUO blend.
Common Cycle
The practitioner reference frames the Tesamorelin / Ipamorelin blend as continuous daily use following Tesamorelin's standard protocol.
- Cycle Length
- Continuous daily use
- Break Before the Next Cycle
- Not cycled — continuous
- What the Research Shows
- No blend-specific long-term trial exists; individual-component Tesamorelin trials (Falutz 2007; Stanley 2014) followed participants for 26–52 weeks
Documented in the practitioner reference; individual-component Tesamorelin trials · Research-practitioner guide
Blend dose is roughly 25% of Tesamorelin's standalone clinical standard; long-term Tesamorelin outcomes are drawn from the higher-dose standalone product, not from this compromise blend dose.
Compound Overview
Current areas of research
Component-level effects. Tesamorelin has substantial peer-reviewed evidence for visceral-fat reduction pharmacology.
- Visceral fat reduction effects build over 6+ months (Tesamorelin-driven at reference doses)
- Ipamorelin GH pulse amplification works acute-time-scale
- IGF-1 elevation and body-composition support
- Combined GH-axis engagement without cortisol / prolactin / ACTH elevation (Ipamorelin's selectivity)
Mechanism of action
The Tesamorelin / Ipamorelin Blend combines two GH-axis peptides at 5 mg each in a single lyophilized vial. The pairing is mechanistically similar to the CJC-1295 / Ipamorelin blend — dual-pathway GH stimulation combining a GHRH-analogue with a ghrelin-receptor agonist — but with a Tesamorelin backbone chosen specifically for its documented visceral-fat-reduction pharmacology. Tesamorelin's peer-reviewed evidence base is anchored in the Falutz 2007 NEJM pivotal trial and the Stanley 2014 JAMA sustained-effect follow-up. That component-level evidence is the reason Tesamorelin, rather than CJC-1295, is the GHRH-analogue component of this specific blend.
The dose trade-off in the 1:1 vial ratio is worth naming honestly. Tesamorelin's research reference amount is 2 mg subcutaneously daily. Ipamorelin's optimal amount per injection is 0.25–0.375 mg. In this 5/5 mg blend, reaching the 2 mg Tesamorelin amount requires injecting 0.4 mL of the reconstituted blend, which delivers 1 mg of Ipamorelin — well above its optimal range. Conversely, holding Ipamorelin at its optimal 0.25–0.375 mg (0.1–0.15 mL of blend) delivers only 0.25–0.375 mg of Tesamorelin — well below its research reference. The practical compromise the Healthy Mango practitioner reference recommends is 0.2 mL per injection, delivering 0.5 mg of each — Tesamorelin below its research reference and Ipamorelin above its optimal.
For researchers new to GH-axis peptides during titration, this compromise dose is often reasonable — it introduces both peptides without overshooting either significantly, and it accepts that Tesamorelin's full documented effect may not be reached at the blend's compromise dose. For researchers targeting the full Tesamorelin visceral-fat-reduction effect, running the two peptides separately would give more control — Tesamorelin at its 2 mg research reference and Ipamorelin at its optimal 0.25–0.375 mg per injection.
Blend-specific human trial evidence does not exist. Component-level evidence is substantial for Tesamorelin (Falutz 2007 NEJM, Stanley 2014 JAMA) and characterised for Ipamorelin (Raun 1998). The combination has not been formally evaluated as a single product. That is the honest evidence framing; the mechanistic rationale for dual-pathway GH stimulation is coherent, and component-level evidence does not automatically transfer to the combination.
- Two-component GH-axis blend: Tesamorelin 5 mg + Ipamorelin 5 mg = 10 mg total
- Component-level evidence for Tesamorelin is substantial; the blend has no combination-specific trial and no regulatory approval
- Inherent 1:1-ratio dose conflict — the reference 0.2 mL compromise dose gives 0.5 mg of each, sub-optimal for the full Tesamorelin research effect
Human research
Tesamorelin's peer-reviewed evidence base is substantial. Falutz 2007 NEJM is the pivotal phase-3 trial of Tesamorelin's visceral-fat-reduction pharmacology. Stanley 2014 JAMA is the sustained-effect follow-up demonstrating continued benefit and safety. Both are the individual-Tesamorelin evidence base — not blend evidence.
Ipamorelin's mechanistic characterisation (Raun 1998) supports the selective ghrelin-agonism story that makes it a cleaner ghrelin-mimetic than the older GHRP series.
The combination has not been formally evaluated as a single product in a randomised trial. Discussions that treat Tesamorelin's component-level evidence as validation of the specific combination are conflating individual-component and combination evidence.
Falutz 2007 NEJM (Tesamorelin pivotal)
Pivotal phase-3 trial of Tesamorelin's visceral-fat-reduction pharmacology.
Stanley 2014 JAMA (Tesamorelin sustained)
Sustained-effect follow-up of Tesamorelin.
Raun 1998 Ipamorelin
Mechanistic characterisation of Ipamorelin's selective ghrelin agonism.
The blend format has no regulatory authorisation. The two components are covered separately on their own compound pages.
No blend-specific human trial has been published.
Safety considerations
Component-level and grey-market research experience.
- Injection-site reactions
- Edema, joint pain, carpal tunnel (Tesamorelin-associated at higher doses)
- IGF-1 elevation with long-term use — monitor
- Blood-sugar changes possible
- Long-term safety of specific two-way combination not characterised
Component-level warnings apply.
- Active cancer — GH and IGF-1 are pro-proliferative
- Pregnancy
- Pituitary or hypothalamic disease
- Allergy to tesamorelin, mannitol, or component excipients
- The blend format has no regulatory approval and is not equivalent to any registered pharmaceutical
Monitoring
- IGF-1 with long-term use
- Glucose response
- Injection-site reactions
- Edema and carpal tunnel signs (Tesamorelin-related at higher doses)
Frequently asked questions
Why does the 1:1 ratio create a dose conflict?
Tesamorelin's research reference amount is 2 mg subcutaneously daily. Ipamorelin's optimal amount is 0.25–0.375 mg per injection. In a 5/5 mg vial at 2.5 mg/mL of each component, delivering 2 mg of Tesamorelin means injecting 0.4 mL — which also delivers 1 mg of Ipamorelin, well above its optimal range. Delivering Ipamorelin at 0.25–0.375 mg means injecting only 0.1–0.15 mL — which delivers only 0.25–0.375 mg of Tesamorelin, well below its research reference. The 1:1 ratio makes it impossible to reach both peptides' optimal amounts simultaneously.
Is the compromise 0.2 mL dose adequate for the Tesamorelin effect?
It is below Tesamorelin's research reference amount. Whether the sub-reference dose still produces meaningful visceral-fat reduction is not well-characterised at scale. Researchers who want the full Tesamorelin effect documented in Falutz 2007 and Stanley 2014 would need to either use the individual peptides at their optimal amounts or accept the Ipamorelin overshoot at 0.4 mL.
Is this blend equivalent to a standalone Tesamorelin preparation?
No. A standalone Tesamorelin preparation gives independent control of the Tesamorelin dose. The blend is a research-supply product combining Tesamorelin with Ipamorelin at a 1:1 ratio, which fixes the two components' relative amounts and creates the dose-conflict trade-off described above. They are different products with different dosing behaviour.
How does this compare to the CJC-1295 / Ipamorelin blend?
Both are dual-pathway GH secretagogue blends with Ipamorelin as the ghrelin-agonist component. The GHRH-analogue components differ: CJC-1295 No DAC is a shorter-acting GHRH analogue for general GH stimulation; Tesamorelin is a longer-acting stabilised GHRH analogue with documented visceral-fat-reduction pharmacology in the peer-reviewed literature. The Tesamorelin blend targets visceral-fat reduction more specifically; the CJC-1295 blend is more general-purpose. The CJC-1295 blend also avoids the specific dose-conflict that the Tesamorelin 1:1 ratio creates.
Is separate Tesamorelin and Ipamorelin better than the blend?
For researchers targeting the full Tesamorelin effect at its 2 mg research reference, separate peptides give the dose flexibility the blend does not — Tesamorelin at 2 mg and Ipamorelin at 0.25–0.375 mg per injection. For new-participant titration or maintenance, the blend's convenience may outweigh its dose-conflict limitation. Understanding the trade-off is what matters.
References
- [1]
A phase 3, randomised, placebo-controlled trial of tesamorelin (a growth hormone–releasing factor analogue) in HIV-infected patients with excess abdominal fat — Falutz J, Allas S, Blot K, et al., New England Journal of Medicine (2007)
- [2]
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation — a randomised clinical trial — Stanley TL, Feldpausch MN, Oh J, et al., JAMA (2014)
- [3]
Ipamorelin, the first selective growth hormone secretagogue — Raun K, Hansen BS, Johansen NL, et al., European Journal of Endocrinology (1998)
- [4]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.